#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Functional neural changes following behavioral therapies and disulfiram for cocaine dependence A growing literature exists on neural correlates of treatment outcome.
1-1	0-10	Functional	_
1-2	11-17	neural	_
1-3	18-25	changes	_
1-4	26-35	following	_
1-5	36-46	behavioral	_
1-6	47-56	therapies	_
1-7	57-60	and	_
1-8	61-71	disulfiram	_
1-9	72-75	for	_
1-10	76-83	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-11	84-94	dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-12	95-96	A	_
1-13	97-104	growing	_
1-14	105-115	literature	_
1-15	116-122	exists	_
1-16	123-125	on	_
1-17	126-132	neural	_
1-18	133-143	correlates	_
1-19	144-146	of	_
1-20	147-156	treatment	_
1-21	157-164	outcome	_
1-22	165-166	.	_

Text=However, different types - or components of - treatment have distinct theorized mechanisms of action.
2-1	167-174	However	_
2-2	175-176	,	_
2-3	177-186	different	_
2-4	187-192	types	_
2-5	193-194	-	_
2-6	195-197	or	_
2-7	198-208	components	_
2-8	209-211	of	_
2-9	212-213	-	_
2-10	214-223	treatment	_
2-11	224-228	have	_
2-12	229-237	distinct	_
2-13	238-247	theorized	_
2-14	248-258	mechanisms	_
2-15	259-261	of	_
2-16	262-268	action	_
2-17	269-270	.	_

Text=And, it is not yet known how changes in neural activity across treatment relate to engagement in different treatment components.
3-1	271-274	And	_
3-2	275-276	,	_
3-3	277-279	it	_
3-4	280-282	is	_
3-5	283-286	not	_
3-6	287-290	yet	_
3-7	291-296	known	_
3-8	297-300	how	_
3-9	301-308	changes	_
3-10	309-311	in	_
3-11	312-318	neural	_
3-12	319-327	activity	_
3-13	328-334	across	_
3-14	335-344	treatment	_
3-15	345-351	relate	_
3-16	352-354	to	_
3-17	355-365	engagement	_
3-18	366-368	in	_
3-19	369-378	different	_
3-20	379-388	treatment	_
3-21	389-399	components	_
3-22	400-401	.	_

Text=Participants with cocaine-use disorders in a randomized clinical trial received cognitive behavioral therapy (CBT) plus, in a 2×2 design, contingency management (CM) or no-CM, and disulfiram or placebo.
4-1	402-414	Participants	_
4-2	415-419	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
4-3	420-431	cocaine-use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
4-4	432-441	disorders	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
4-5	442-444	in	_
4-6	445-446	a	_
4-7	447-457	randomized	_
4-8	458-466	clinical	_
4-9	467-472	trial	_
4-10	473-481	received	_
4-11	482-491	cognitive	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
4-12	492-502	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
4-13	503-510	therapy	_
4-14	511-512	(	_
4-15	513-516	CBT	_
4-16	517-518	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-17	519-523	plus	_
4-18	524-525	,	_
4-19	526-528	in	_
4-20	529-530	a	_
4-21	531-534	2×2	_
4-22	535-541	design	_
4-23	542-543	,	_
4-24	544-555	contingency	_
4-25	556-566	management	_
4-26	567-568	(	_
4-27	569-571	CM	_
4-28	572-573	)	_
4-29	574-576	or	_
4-30	577-582	no-CM	_
4-31	583-584	,	_
4-32	585-588	and	_
4-33	589-599	disulfiram	_
4-34	600-602	or	_
4-35	603-610	placebo	_
4-36	611-612	.	_

Text=Participants performed an fMRI Stroop Task, a measure of cognitive-control, at the beginning of and after the 12-week treatment.
5-1	613-625	Participants	_
5-2	626-635	performed	_
5-3	636-638	an	_
5-4	639-643	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
5-5	644-650	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
5-6	651-655	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
5-7	656-657	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
5-8	658-659	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
5-9	660-667	measure	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
5-10	668-670	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
5-11	671-688	cognitive-control	_
5-12	689-690	,	_
5-13	691-693	at	_
5-14	694-697	the	_
5-15	698-707	beginning	_
5-16	708-710	of	_
5-17	711-714	and	_
5-18	715-720	after	_
5-19	721-724	the	_
5-20	725-732	12-week	_
5-21	733-742	treatment	_
5-22	743-744	.	_

Text=Analyses assessed changes in Stroop-related neural activity within the sample overall and assessed how changes in Stroop-related activity correlated with measures of treatment process specific to each form of treatment (i.e., participation in CBT sessions, receipt of CM prizes, administration of disulfiram pills).
6-1	745-753	Analyses	_
6-2	754-762	assessed	_
6-3	763-770	changes	_
6-4	771-773	in	_
6-5	774-788	Stroop-related	_
6-6	789-795	neural	_
6-7	796-804	activity	_
6-8	805-811	within	_
6-9	812-815	the	_
6-10	816-822	sample	_
6-11	823-830	overall	_
6-12	831-834	and	_
6-13	835-843	assessed	_
6-14	844-847	how	_
6-15	848-855	changes	_
6-16	856-858	in	_
6-17	859-873	Stroop-related	_
6-18	874-882	activity	_
6-19	883-893	correlated	_
6-20	894-898	with	_
6-21	899-907	measures	_
6-22	908-910	of	_
6-23	911-920	treatment	_
6-24	921-928	process	_
6-25	929-937	specific	_
6-26	938-940	to	_
6-27	941-945	each	_
6-28	946-950	form	_
6-29	951-953	of	_
6-30	954-963	treatment	_
6-31	964-965	(	_
6-32	966-970	i.e.	_
6-33	971-972	,	_
6-34	973-986	participation	_
6-35	987-989	in	_
6-36	990-993	CBT	_
6-37	994-1002	sessions	_
6-38	1003-1004	,	_
6-39	1005-1012	receipt	_
6-40	1013-1015	of	_
6-41	1016-1018	CM	_
6-42	1019-1025	prizes	_
6-43	1026-1027	,	_
6-44	1028-1042	administration	_
6-45	1043-1045	of	_
6-46	1046-1056	disulfiram	_
6-47	1057-1062	pills	_
6-48	1063-1064	)	_
6-49	1065-1066	.	_

Text=Within the sample overall, compared to beginning-of-treatment, post-treatment Stroop-related neural activity was diminished in hippocampus, thalamus, cingulate, precentral, post/precentral gyrus, and precuneus and culmen regions (pFWE <.05).
7-1	1067-1073	Within	_
7-2	1074-1077	the	_
7-3	1078-1084	sample	_
7-4	1085-1092	overall	_
7-5	1093-1094	,	_
7-6	1095-1103	compared	_
7-7	1104-1106	to	_
7-8	1107-1129	beginning-of-treatment	_
7-9	1130-1131	,	_
7-10	1132-1146	post-treatment	_
7-11	1147-1161	Stroop-related	_
7-12	1162-1168	neural	_
7-13	1169-1177	activity	_
7-14	1178-1181	was	_
7-15	1182-1192	diminished	_
7-16	1193-1195	in	_
7-17	1196-1207	hippocampus	_
7-18	1208-1209	,	_
7-19	1210-1218	thalamus	_
7-20	1219-1220	,	_
7-21	1221-1230	cingulate	_
7-22	1231-1232	,	_
7-23	1233-1243	precentral	_
7-24	1244-1245	,	_
7-25	1246-1261	post/precentral	_
7-26	1262-1267	gyrus	_
7-27	1268-1269	,	_
7-28	1270-1273	and	_
7-29	1274-1283	precuneus	_
7-30	1284-1287	and	_
7-31	1288-1294	culmen	_
7-32	1295-1302	regions	_
7-33	1303-1304	(	_
7-34	1305-1309	pFWE	_
7-35	1310-1311	<	_
7-36	1312-1315	.05	_
7-37	1316-1317	)	_
7-38	1318-1319	.	_

Text=In separate whole-brain correlation analyses, greater reductions in Stroop-related activity were associated with more treatment engagement: ‘ CBT sessions ’ with precentral gyrus, inferior parietal lobule, middle and medial frontal gyrus; ‘ CM prizes ’ with postcentral frontal gyrus.
8-1	1320-1322	In	_
8-2	1323-1331	separate	_
8-3	1332-1343	whole-brain	_
8-4	1344-1355	correlation	_
8-5	1356-1364	analyses	_
8-6	1365-1366	,	_
8-7	1367-1374	greater	_
8-8	1375-1385	reductions	_
8-9	1386-1388	in	_
8-10	1389-1403	Stroop-related	_
8-11	1404-1412	activity	_
8-12	1413-1417	were	_
8-13	1418-1428	associated	_
8-14	1429-1433	with	_
8-15	1434-1438	more	_
8-16	1439-1448	treatment	_
8-17	1449-1459	engagement	_
8-18	1460-1461	:	_
8-19	1462-1463	‘	_
8-20	1464-1467	CBT	_
8-21	1468-1476	sessions	_
8-22	1477-1478	’	_
8-23	1479-1483	with	_
8-24	1484-1494	precentral	_
8-25	1495-1500	gyrus	_
8-26	1501-1502	,	_
8-27	1503-1511	inferior	_
8-28	1512-1520	parietal	_
8-29	1521-1527	lobule	_
8-30	1528-1529	,	_
8-31	1530-1536	middle	_
8-32	1537-1540	and	_
8-33	1541-1547	medial	_
8-34	1548-1555	frontal	_
8-35	1556-1561	gyrus	_
8-36	1562-1563	;	_
8-37	1564-1565	‘	_
8-38	1566-1568	CM	_
8-39	1569-1575	prizes	_
8-40	1576-1577	’	_
8-41	1578-1582	with	_
8-42	1583-1594	postcentral	_
8-43	1595-1602	frontal	_
8-44	1603-1608	gyrus	_
8-45	1609-1610	.	_

Text=Disulfiram ‘ medication days ’ were not associated with changes in Stroop-related activity.
9-1	1611-1621	Disulfiram	_
9-2	1622-1623	‘	_
9-3	1624-1634	medication	_
9-4	1635-1639	days	_
9-5	1640-1641	’	_
9-6	1642-1646	were	_
9-7	1647-1650	not	_
9-8	1651-1661	associated	_
9-9	1662-1666	with	_
9-10	1667-1674	changes	_
9-11	1675-1677	in	_
9-12	1678-1692	Stroop-related	_
9-13	1693-1701	activity	_
9-14	1702-1703	.	_

Text=Findings suggest key process indicators of CBT and CM may be associated with functional changes in cognitive-control-related neurocircuitry.
10-1	1704-1712	Findings	_
10-2	1713-1720	suggest	_
10-3	1721-1724	key	_
10-4	1725-1732	process	_
10-5	1733-1743	indicators	_
10-6	1744-1746	of	_
10-7	1747-1750	CBT	_
10-8	1751-1754	and	_
10-9	1755-1757	CM	_
10-10	1758-1761	may	_
10-11	1762-1764	be	_
10-12	1765-1775	associated	_
10-13	1776-1780	with	_
10-14	1781-1791	functional	_
10-15	1792-1799	changes	_
10-16	1800-1802	in	_
10-17	1803-1828	cognitive-control-related	_
10-18	1829-1843	neurocircuitry	_
10-19	1844-1845	.	_

Text=Materials and Methods Participants Treatment-seeking participants were recruited to the fMRI study prior to treatment randomization in an RCT for CUD.
11-1	1846-1855	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-2	1856-1859	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-3	1860-1867	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-4	1868-1880	Participants	_
11-5	1881-1898	Treatment-seeking	_
11-6	1899-1911	participants	_
11-7	1912-1916	were	_
11-8	1917-1926	recruited	_
11-9	1927-1929	to	_
11-10	1930-1933	the	_
11-11	1934-1938	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
11-12	1939-1944	study	_
11-13	1945-1950	prior	_
11-14	1951-1953	to	_
11-15	1954-1963	treatment	_
11-16	1964-1977	randomization	_
11-17	1978-1980	in	_
11-18	1981-1983	an	_
11-19	1984-1987	RCT	_
11-20	1988-1991	for	_
11-21	1992-1995	CUD	_
11-22	1996-1997	.	_

Text=Participants were 18 years or older, recruited from a community-based outpatient treatment center, met DSM-IV criteria for current cocaine dependence and did not meet current dependence criteria for other illicit drugs.
12-1	1998-2010	Participants	_
12-2	2011-2015	were	_
12-3	2016-2018	18	_
12-4	2019-2024	years	_
12-5	2025-2027	or	_
12-6	2028-2033	older	_
12-7	2034-2035	,	_
12-8	2036-2045	recruited	_
12-9	2046-2050	from	_
12-10	2051-2052	a	_
12-11	2053-2068	community-based	_
12-12	2069-2079	outpatient	_
12-13	2080-2089	treatment	_
12-14	2090-2096	center	_
12-15	2097-2098	,	_
12-16	2099-2102	met	_
12-17	2103-2109	DSM-IV	_
12-18	2110-2118	criteria	_
12-19	2119-2122	for	_
12-20	2123-2130	current	_
12-21	2131-2138	cocaine	_
12-22	2139-2149	dependence	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
12-23	2150-2153	and	_
12-24	2154-2157	did	_
12-25	2158-2161	not	_
12-26	2162-2166	meet	_
12-27	2167-2174	current	_
12-28	2175-2185	dependence	_
12-29	2186-2194	criteria	_
12-30	2195-2198	for	_
12-31	2199-2204	other	_
12-32	2205-2212	illicit	_
12-33	2213-2218	drugs	_
12-34	2219-2220	.	_

Text=Other exclusion criteria included lifetime psychotic or bipolar disorder, current suicidal or homicidal ideation or current medical condition that would contraindicate disulfiram treatment (e.g.
13-1	2221-2226	Other	_
13-2	2227-2236	exclusion	_
13-3	2237-2245	criteria	_
13-4	2246-2254	included	_
13-5	2255-2263	lifetime	_
13-6	2264-2273	psychotic	_
13-7	2274-2276	or	_
13-8	2277-2284	bipolar	_
13-9	2285-2293	disorder	_
13-10	2294-2295	,	_
13-11	2296-2303	current	_
13-12	2304-2312	suicidal	_
13-13	2313-2315	or	_
13-14	2316-2325	homicidal	_
13-15	2326-2334	ideation	_
13-16	2335-2337	or	_
13-17	2338-2345	current	_
13-18	2346-2353	medical	_
13-19	2354-2363	condition	_
13-20	2364-2368	that	_
13-21	2369-2374	would	_
13-22	2375-2389	contraindicate	_
13-23	2390-2400	disulfiram	_
13-24	2401-2410	treatment	_
13-25	2411-2412	(	_
13-26	2413-2416	e.g	_
13-27	2417-2418	.	_

Text=hepatic or cardiac problems, hypertension, pregnancy).
14-1	2419-2426	hepatic	_
14-2	2427-2429	or	_
14-3	2430-2437	cardiac	_
14-4	2438-2446	problems	_
14-5	2447-2448	,	_
14-6	2449-2461	hypertension	_
14-7	2462-2463	,	_
14-8	2464-2473	pregnancy	_
14-9	2474-2475	)	_
14-10	2476-2477	.	_

Text=RCT participants were offered participation in the fMRI component if they did not report claustrophobia, colorblindness, history of severe head trauma with loss of consciousness, or metallic implants contraindicated in MRI.
15-1	2478-2481	RCT	http://maven.renci.org/NeuroBridge/neurobridge#RandomizedControlTrial
15-2	2482-2494	participants	_
15-3	2495-2499	were	_
15-4	2500-2507	offered	_
15-5	2508-2521	participation	_
15-6	2522-2524	in	_
15-7	2525-2528	the	_
15-8	2529-2533	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
15-9	2534-2543	component	_
15-10	2544-2546	if	_
15-11	2547-2551	they	_
15-12	2552-2555	did	_
15-13	2556-2559	not	_
15-14	2560-2566	report	_
15-15	2567-2581	claustrophobia	_
15-16	2582-2583	,	_
15-17	2584-2598	colorblindness	_
15-18	2599-2600	,	_
15-19	2601-2608	history	_
15-20	2609-2611	of	_
15-21	2612-2618	severe	_
15-22	2619-2623	head	_
15-23	2624-2630	trauma	_
15-24	2631-2635	with	_
15-25	2636-2640	loss	_
15-26	2641-2643	of	_
15-27	2644-2657	consciousness	_
15-28	2658-2659	,	_
15-29	2660-2662	or	_
15-30	2663-2671	metallic	_
15-31	2672-2680	implants	_
15-32	2681-2696	contraindicated	_
15-33	2697-2699	in	_
15-34	2700-2703	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
15-35	2704-2705	.	_

Text=Of 99 RCT participants, 35 completed fMRI scans at in the beginning-of-treatment and following treatment.
16-1	2706-2708	Of	_
16-2	2709-2711	99	_
16-3	2712-2715	RCT	_
16-4	2716-2728	participants	_
16-5	2729-2730	,	_
16-6	2731-2733	35	_
16-7	2734-2743	completed	_
16-8	2744-2748	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
16-9	2749-2754	scans	_
16-10	2755-2757	at	_
16-11	2758-2760	in	_
16-12	2761-2764	the	_
16-13	2765-2787	beginning-of-treatment	_
16-14	2788-2791	and	_
16-15	2792-2801	following	_
16-16	2802-2811	treatment	_
16-17	2812-2813	.	_

Text=26 of whom were included in the current fMRI analyses (N=9 excluded due to delayed timing of scans relative to beginning-of-treatment or post-treatment, or to insufficient treatment exposure; for details see Supplementary Materials).
17-1	2814-2816	26	_
17-2	2817-2819	of	_
17-3	2820-2824	whom	_
17-4	2825-2829	were	_
17-5	2830-2838	included	_
17-6	2839-2841	in	_
17-7	2842-2845	the	_
17-8	2846-2853	current	_
17-9	2854-2858	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
17-10	2859-2867	analyses	_
17-11	2868-2869	(	_
17-12	2870-2873	N=9	_
17-13	2874-2882	excluded	_
17-14	2883-2886	due	_
17-15	2887-2889	to	_
17-16	2890-2897	delayed	_
17-17	2898-2904	timing	_
17-18	2905-2907	of	_
17-19	2908-2913	scans	_
17-20	2914-2922	relative	_
17-21	2923-2925	to	_
17-22	2926-2948	beginning-of-treatment	_
17-23	2949-2951	or	_
17-24	2952-2966	post-treatment	_
17-25	2967-2968	,	_
17-26	2969-2971	or	_
17-27	2972-2974	to	_
17-28	2975-2987	insufficient	_
17-29	2988-2997	treatment	_
17-30	2998-3006	exposure	_
17-31	3007-3008	;	_
17-32	3009-3012	for	_
17-33	3013-3020	details	_
17-34	3021-3024	see	_
17-35	3025-3038	Supplementary	_
17-36	3039-3048	Materials	_
17-37	3049-3050	)	_
17-38	3051-3052	.	_

Text=This study was approved by a human subjects Institutional Review Board and participants provided written informed consent prior to participation.
18-1	3053-3057	This	_
18-2	3058-3063	study	_
18-3	3064-3067	was	_
18-4	3068-3076	approved	_
18-5	3077-3079	by	_
18-6	3080-3081	a	_
18-7	3082-3087	human	_
18-8	3088-3096	subjects	_
18-9	3097-3110	Institutional	_
18-10	3111-3117	Review	_
18-11	3118-3123	Board	_
18-12	3124-3127	and	_
18-13	3128-3140	participants	_
18-14	3141-3149	provided	_
18-15	3150-3157	written	_
18-16	3158-3166	informed	_
18-17	3167-3174	consent	_
18-18	3175-3180	prior	_
18-19	3181-3183	to	_
18-20	3184-3197	participation	_
18-21	3198-3199	.	_

Text=Treatment and Clinical Assessments RCT methods are reported in full elsewhere.
19-1	3200-3209	Treatment	_
19-2	3210-3213	and	_
19-3	3214-3222	Clinical	_
19-4	3223-3234	Assessments	_
19-5	3235-3238	RCT	_
19-6	3239-3246	methods	_
19-7	3247-3250	are	_
19-8	3251-3259	reported	_
19-9	3260-3262	in	_
19-10	3263-3267	full	_
19-11	3268-3277	elsewhere	_
19-12	3278-3279	.	_

Text=Briefly, treatment lasted 12 weeks, and all participants were offered CBT.
20-1	3280-3287	Briefly	_
20-2	3288-3289	,	_
20-3	3290-3299	treatment	_
20-4	3300-3306	lasted	_
20-5	3307-3309	12	_
20-6	3310-3315	weeks	_
20-7	3316-3317	,	_
20-8	3318-3321	and	_
20-9	3322-3325	all	_
20-10	3326-3338	participants	_
20-11	3339-3343	were	_
20-12	3344-3351	offered	_
20-13	3352-3355	CBT	_
20-14	3356-3357	.	_

Text=In addition, all participants included in the fMRI analyses were randomized to either disulfiram (N=10) or placebo (N=16) and CM (N=14) or no-CM (N=12) in a factorial design, resulting in four treatment conditions: 1) CBT+ CM + disulfiram (N=4), 2) CBT + CM + placebo (N=10), 3) CBT + disulfiram (N=6), 4) CBT + placebo (N=6).
21-1	3358-3360	In	_
21-2	3361-3369	addition	_
21-3	3370-3371	,	_
21-4	3372-3375	all	_
21-5	3376-3388	participants	_
21-6	3389-3397	included	_
21-7	3398-3400	in	_
21-8	3401-3404	the	_
21-9	3405-3409	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
21-10	3410-3418	analyses	_
21-11	3419-3423	were	_
21-12	3424-3434	randomized	_
21-13	3435-3437	to	_
21-14	3438-3444	either	_
21-15	3445-3455	disulfiram	_
21-16	3456-3457	(	_
21-17	3458-3462	N=10	_
21-18	3463-3464	)	_
21-19	3465-3467	or	_
21-20	3468-3475	placebo	_
21-21	3476-3477	(	_
21-22	3478-3482	N=16	_
21-23	3483-3484	)	_
21-24	3485-3488	and	_
21-25	3489-3491	CM	_
21-26	3492-3493	(	_
21-27	3494-3498	N=14	_
21-28	3499-3500	)	_
21-29	3501-3503	or	_
21-30	3504-3509	no-CM	_
21-31	3510-3511	(	_
21-32	3512-3516	N=12	_
21-33	3517-3518	)	_
21-34	3519-3521	in	_
21-35	3522-3523	a	_
21-36	3524-3533	factorial	_
21-37	3534-3540	design	_
21-38	3541-3542	,	_
21-39	3543-3552	resulting	_
21-40	3553-3555	in	_
21-41	3556-3560	four	_
21-42	3561-3570	treatment	_
21-43	3571-3581	conditions	_
21-44	3582-3583	:	_
21-45	3584-3585	1	_
21-46	3586-3587	)	_
21-47	3588-3592	CBT+	_
21-48	3593-3595	CM	_
21-49	3596-3597	+	_
21-50	3598-3608	disulfiram	_
21-51	3609-3610	(	_
21-52	3611-3614	N=4	_
21-53	3615-3616	)	_
21-54	3617-3618	,	_
21-55	3619-3620	2	_
21-56	3621-3622	)	_
21-57	3623-3626	CBT	_
21-58	3627-3628	+	_
21-59	3629-3631	CM	_
21-60	3632-3633	+	_
21-61	3634-3641	placebo	_
21-62	3642-3643	(	_
21-63	3644-3648	N=10	_
21-64	3649-3650	)	_
21-65	3651-3652	,	_
21-66	3653-3654	3	_
21-67	3655-3656	)	_
21-68	3657-3660	CBT	_
21-69	3661-3662	+	_
21-70	3663-3673	disulfiram	_
21-71	3674-3675	(	_
21-72	3676-3679	N=6	_
21-73	3680-3681	)	_
21-74	3682-3683	,	_
21-75	3684-3685	4	_
21-76	3686-3687	)	_
21-77	3688-3691	CBT	_
21-78	3692-3693	+	_
21-79	3694-3701	placebo	_
21-80	3702-3703	(	_
21-81	3704-3707	N=6	_
21-82	3708-3709	)	_
21-83	3710-3711	.	_

Text=Participants were asked to attend the clinic three times per week during the 12-week protocol; medication was dispensed and urine specimens were collected at each clinic visit.
22-1	3712-3724	Participants	_
22-2	3725-3729	were	_
22-3	3730-3735	asked	_
22-4	3736-3738	to	_
22-5	3739-3745	attend	_
22-6	3746-3749	the	_
22-7	3750-3756	clinic	_
22-8	3757-3762	three	_
22-9	3763-3768	times	_
22-10	3769-3772	per	_
22-11	3773-3777	week	_
22-12	3778-3784	during	_
22-13	3785-3788	the	_
22-14	3789-3796	12-week	_
22-15	3797-3805	protocol	_
22-16	3806-3807	;	_
22-17	3808-3818	medication	_
22-18	3819-3822	was	_
22-19	3823-3832	dispensed	_
22-20	3833-3836	and	_
22-21	3837-3842	urine	_
22-22	3843-3852	specimens	_
22-23	3853-3857	were	_
22-24	3858-3867	collected	_
22-25	3868-3870	at	_
22-26	3871-3875	each	_
22-27	3876-3882	clinic	_
22-28	3883-3888	visit	_
22-29	3889-3890	.	_

Text=All in-person treatment delivery, tracking of treatment adherence and tracking monitoring of substance use occurred in those thrice-weekly visits.
23-1	3891-3894	All	_
23-2	3895-3904	in-person	_
23-3	3905-3914	treatment	_
23-4	3915-3923	delivery	_
23-5	3924-3925	,	_
23-6	3926-3934	tracking	_
23-7	3935-3937	of	_
23-8	3938-3947	treatment	_
23-9	3948-3957	adherence	_
23-10	3958-3961	and	_
23-11	3962-3970	tracking	_
23-12	3971-3981	monitoring	_
23-13	3982-3984	of	_
23-14	3985-3994	substance	_
23-15	3995-3998	use	_
23-16	3999-4007	occurred	_
23-17	4008-4010	in	_
23-18	4011-4016	those	_
23-19	4017-4030	thrice-weekly	_
23-20	4031-4037	visits	_
23-21	4038-4039	.	_

Text=Due to the limited sample sizes for the four treatment cells within the fMRI sample, analyses focused on the entire sample or comparing disulfiram versus placebo, or CM versus no-CM.
24-1	4040-4043	Due	_
24-2	4044-4046	to	_
24-3	4047-4050	the	_
24-4	4051-4058	limited	_
24-5	4059-4065	sample	_
24-6	4066-4071	sizes	_
24-7	4072-4075	for	_
24-8	4076-4079	the	_
24-9	4080-4084	four	_
24-10	4085-4094	treatment	_
24-11	4095-4100	cells	_
24-12	4101-4107	within	_
24-13	4108-4111	the	_
24-14	4112-4116	fMRI	_
24-15	4117-4123	sample	_
24-16	4124-4125	,	_
24-17	4126-4134	analyses	_
24-18	4135-4142	focused	_
24-19	4143-4145	on	_
24-20	4146-4149	the	_
24-21	4150-4156	entire	_
24-22	4157-4163	sample	_
24-23	4164-4166	or	_
24-24	4167-4176	comparing	_
24-25	4177-4187	disulfiram	_
24-26	4188-4194	versus	_
24-27	4195-4202	placebo	_
24-28	4203-4204	,	_
24-29	4205-4207	or	_
24-30	4208-4210	CM	_
24-31	4211-4217	versus	_
24-32	4218-4223	no-CM	_
24-33	4224-4225	.	_

Text=Cognitive Behavioral Therapy (CBT) Weekly 50-minute individual CBT sessions were offered as per the CBT manual, delivered by doctoral-level clinicians with CBT experience and demonstrated competence.
25-1	4226-4235	Cognitive	http://maven.renci.org/NeuroBridge/neurobridge#DisruptiveBehaviorDisorder
25-2	4236-4246	Behavioral	http://maven.renci.org/NeuroBridge/neurobridge#DisruptiveBehaviorDisorder
25-3	4247-4254	Therapy	http://maven.renci.org/NeuroBridge/neurobridge#DisruptiveBehaviorDisorder
25-4	4255-4256	(	http://maven.renci.org/NeuroBridge/neurobridge#DisruptiveBehaviorDisorder
25-5	4257-4260	CBT	http://maven.renci.org/NeuroBridge/neurobridge#DisruptiveBehaviorDisorder
25-6	4261-4262	)	http://maven.renci.org/NeuroBridge/neurobridge#DisruptiveBehaviorDisorder
25-7	4263-4269	Weekly	_
25-8	4270-4279	50-minute	_
25-9	4280-4290	individual	_
25-10	4291-4294	CBT	_
25-11	4295-4303	sessions	_
25-12	4304-4308	were	_
25-13	4309-4316	offered	_
25-14	4317-4319	as	_
25-15	4320-4323	per	_
25-16	4324-4327	the	_
25-17	4328-4331	CBT	_
25-18	4332-4338	manual	_
25-19	4339-4340	,	_
25-20	4341-4350	delivered	_
25-21	4351-4353	by	_
25-22	4354-4368	doctoral-level	_
25-23	4369-4379	clinicians	_
25-24	4380-4384	with	_
25-25	4385-4388	CBT	_
25-26	4389-4399	experience	_
25-27	4400-4403	and	_
25-28	4404-4416	demonstrated	_
25-29	4417-4427	competence	_
25-30	4428-4429	.	_

Text=The primary process indicator for CBT was number of CBT sessions attended (see Table 1).
26-1	4430-4433	The	_
26-2	4434-4441	primary	_
26-3	4442-4449	process	_
26-4	4450-4459	indicator	_
26-5	4460-4463	for	_
26-6	4464-4467	CBT	_
26-7	4468-4471	was	_
26-8	4472-4478	number	_
26-9	4479-4481	of	_
26-10	4482-4485	CBT	_
26-11	4486-4494	sessions	_
26-12	4495-4503	attended	_
26-13	4504-4505	(	_
26-14	4506-4509	see	_
26-15	4510-4515	Table	_
26-16	4516-4517	1	_
26-17	4518-4519	)	_
26-18	4520-4521	.	_

Text=CBT aims to promote abstinence by teaching and promoting practice of behavioral and cognitive control strategies (e.g., coping with craving, improving decision making skills).
27-1	4522-4525	CBT	_
27-2	4526-4530	aims	_
27-3	4531-4533	to	_
27-4	4534-4541	promote	_
27-5	4542-4552	abstinence	_
27-6	4553-4555	by	_
27-7	4556-4564	teaching	_
27-8	4565-4568	and	_
27-9	4569-4578	promoting	_
27-10	4579-4587	practice	_
27-11	4588-4590	of	_
27-12	4591-4601	behavioral	_
27-13	4602-4605	and	_
27-14	4606-4615	cognitive	_
27-15	4616-4623	control	_
27-16	4624-4634	strategies	_
27-17	4635-4636	(	_
27-18	4637-4641	e.g.	_
27-19	4642-4643	,	_
27-20	4644-4650	coping	_
27-21	4651-4655	with	_
27-22	4656-4663	craving	_
27-23	4664-4665	,	_
27-24	4666-4675	improving	_
27-25	4676-4684	decision	_
27-26	4685-4691	making	_
27-27	4692-4698	skills	_
27-28	4699-4700	)	_
27-29	4701-4702	.	_

Text=CBT homework, assigned at each session, offers the opportunity to practice applying the skills discussed in CBT sessions.
28-1	4703-4706	CBT	_
28-2	4707-4715	homework	_
28-3	4716-4717	,	_
28-4	4718-4726	assigned	_
28-5	4727-4729	at	_
28-6	4730-4734	each	_
28-7	4735-4742	session	_
28-8	4743-4744	,	_
28-9	4745-4751	offers	_
28-10	4752-4755	the	_
28-11	4756-4767	opportunity	_
28-12	4768-4770	to	_
28-13	4771-4779	practice	_
28-14	4780-4788	applying	_
28-15	4789-4792	the	_
28-16	4793-4799	skills	_
28-17	4800-4809	discussed	_
28-18	4810-4812	in	_
28-19	4813-4816	CBT	_
28-20	4817-4825	sessions	_
28-21	4826-4827	.	_

Text=Contingency Management (CM) All participants were randomly assigned to receive contingency management (CM group) or not (no-CM group).
29-1	4828-4839	Contingency	_
29-2	4840-4850	Management	_
29-3	4851-4852	(	_
29-4	4853-4855	CM	_
29-5	4856-4857	)	_
29-6	4858-4861	All	_
29-7	4862-4874	participants	_
29-8	4875-4879	were	_
29-9	4880-4888	randomly	_
29-10	4889-4897	assigned	_
29-11	4898-4900	to	_
29-12	4901-4908	receive	_
29-13	4909-4920	contingency	_
29-14	4921-4931	management	_
29-15	4932-4933	(	_
29-16	4934-4936	CM	_
29-17	4937-4942	group	_
29-18	4943-4944	)	_
29-19	4945-4947	or	_
29-20	4948-4951	not	_
29-21	4952-4953	(	_
29-22	4954-4959	no-CM	_
29-23	4960-4965	group	_
29-24	4966-4967	)	_
29-25	4968-4969	.	_

Text=Those assigned to CM could draw at least one prize chance from a bowl each time they demonstrated abstinence (submitted a cocaine-free urine specimen) or pill adherence (staff witnessed ingestion of study capsule).
30-1	4970-4975	Those	_
30-2	4976-4984	assigned	_
30-3	4985-4987	to	_
30-4	4988-4990	CM	_
30-5	4991-4996	could	_
30-6	4997-5001	draw	_
30-7	5002-5004	at	_
30-8	5005-5010	least	_
30-9	5011-5014	one	_
30-10	5015-5020	prize	_
30-11	5021-5027	chance	_
30-12	5028-5032	from	_
30-13	5033-5034	a	_
30-14	5035-5039	bowl	_
30-15	5040-5044	each	_
30-16	5045-5049	time	_
30-17	5050-5054	they	_
30-18	5055-5067	demonstrated	_
30-19	5068-5078	abstinence	_
30-20	5079-5080	(	_
30-21	5081-5090	submitted	_
30-22	5091-5092	a	_
30-23	5093-5105	cocaine-free	_
30-24	5106-5111	urine	_
30-25	5112-5120	specimen	_
30-26	5121-5122	)	_
30-27	5123-5125	or	_
30-28	5126-5130	pill	_
30-29	5131-5140	adherence	_
30-30	5141-5142	(	_
30-31	5143-5148	staff	_
30-32	5149-5158	witnessed	_
30-33	5159-5168	ingestion	_
30-34	5169-5171	of	_
30-35	5172-5177	study	_
30-36	5178-5185	capsule	_
30-37	5186-5187	)	_
30-38	5188-5189	.	_

Text=Consistent with previously established procedures, the number of CM draws per reinforced behavior (abstinence, pill adherence) escalated (up to a maximum of 7 draws) with each consecutive demonstration of abstinence or adherence.
31-1	5190-5200	Consistent	_
31-2	5201-5205	with	_
31-3	5206-5216	previously	_
31-4	5217-5228	established	_
31-5	5229-5239	procedures	_
31-6	5240-5241	,	_
31-7	5242-5245	the	_
31-8	5246-5252	number	_
31-9	5253-5255	of	_
31-10	5256-5258	CM	_
31-11	5259-5264	draws	_
31-12	5265-5268	per	_
31-13	5269-5279	reinforced	_
31-14	5280-5288	behavior	_
31-15	5289-5290	(	_
31-16	5291-5301	abstinence	_
31-17	5302-5303	,	_
31-18	5304-5308	pill	_
31-19	5309-5318	adherence	_
31-20	5319-5320	)	_
31-21	5321-5330	escalated	_
31-22	5331-5332	(	_
31-23	5333-5335	up	_
31-24	5336-5338	to	_
31-25	5339-5340	a	_
31-26	5341-5348	maximum	_
31-27	5349-5351	of	_
31-28	5352-5353	7	_
31-29	5354-5359	draws	_
31-30	5360-5361	)	_
31-31	5362-5366	with	_
31-32	5367-5371	each	_
31-33	5372-5383	consecutive	_
31-34	5384-5397	demonstration	_
31-35	5398-5400	of	_
31-36	5401-5411	abstinence	_
31-37	5412-5414	or	_
31-38	5415-5424	adherence	_
31-39	5425-5426	.	_

Text=If patients missed a scheduled visit or failed to submit a cocaine-negative urine, the number of prize draws for subsequent reinforced behaviors would drop back down to one (for CM methods details, see Supplementary Methods and.
32-1	5427-5429	If	_
32-2	5430-5438	patients	_
32-3	5439-5445	missed	_
32-4	5446-5447	a	_
32-5	5448-5457	scheduled	_
32-6	5458-5463	visit	_
32-7	5464-5466	or	_
32-8	5467-5473	failed	_
32-9	5474-5476	to	_
32-10	5477-5483	submit	_
32-11	5484-5485	a	_
32-12	5486-5502	cocaine-negative	_
32-13	5503-5508	urine	_
32-14	5509-5510	,	_
32-15	5511-5514	the	_
32-16	5515-5521	number	_
32-17	5522-5524	of	_
32-18	5525-5530	prize	_
32-19	5531-5536	draws	_
32-20	5537-5540	for	_
32-21	5541-5551	subsequent	_
32-22	5552-5562	reinforced	_
32-23	5563-5572	behaviors	_
32-24	5573-5578	would	_
32-25	5579-5583	drop	_
32-26	5584-5588	back	_
32-27	5589-5593	down	_
32-28	5594-5596	to	_
32-29	5597-5600	one	_
32-30	5601-5602	(	_
32-31	5603-5606	for	_
32-32	5607-5609	CM	_
32-33	5610-5617	methods	_
32-34	5618-5625	details	_
32-35	5626-5627	,	_
32-36	5628-5631	see	_
32-37	5632-5645	Supplementary	_
32-38	5646-5653	Methods	_
32-39	5654-5657	and	_
32-40	5658-5659	.	_

Text=The primary process indicator for exposure to CM in these analyses was the sum of total prizes drawn across treatment (‘ number of CM prizes ’; Table 1).
33-1	5660-5663	The	_
33-2	5664-5671	primary	_
33-3	5672-5679	process	_
33-4	5680-5689	indicator	_
33-5	5690-5693	for	_
33-6	5694-5702	exposure	_
33-7	5703-5705	to	_
33-8	5706-5708	CM	_
33-9	5709-5711	in	_
33-10	5712-5717	these	_
33-11	5718-5726	analyses	_
33-12	5727-5730	was	_
33-13	5731-5734	the	_
33-14	5735-5738	sum	_
33-15	5739-5741	of	_
33-16	5742-5747	total	_
33-17	5748-5754	prizes	_
33-18	5755-5760	drawn	_
33-19	5761-5767	across	_
33-20	5768-5777	treatment	_
33-21	5778-5779	(	_
33-22	5780-5781	‘	_
33-23	5782-5788	number	_
33-24	5789-5791	of	_
33-25	5792-5794	CM	_
33-26	5795-5801	prizes	_
33-27	5802-5803	’	_
33-28	5804-5805	;	_
33-29	5806-5811	Table	_
33-30	5812-5813	1	_
33-31	5814-5815	)	_
33-32	5816-5817	.	_

Text=Disulfiram All participants were randomly assigned to either disulfiram (250 mg daily) or identical placebo capsules, administered in a double-blind manner.
34-1	5818-5828	Disulfiram	_
34-2	5829-5832	All	_
34-3	5833-5845	participants	_
34-4	5846-5850	were	_
34-5	5851-5859	randomly	_
34-6	5860-5868	assigned	_
34-7	5869-5871	to	_
34-8	5872-5878	either	_
34-9	5879-5889	disulfiram	_
34-10	5890-5891	(	_
34-11	5892-5895	250	_
34-12	5896-5898	mg	_
34-13	5899-5904	daily	_
34-14	5905-5906	)	_
34-15	5907-5909	or	_
34-16	5910-5919	identical	_
34-17	5920-5927	placebo	_
34-18	5928-5936	capsules	_
34-19	5937-5938	,	_
34-20	5939-5951	administered	_
34-21	5952-5954	in	_
34-22	5955-5956	a	_
34-23	5957-5969	double-blind	_
34-24	5970-5976	manner	_
34-25	5977-5978	.	_

Text=This disulfiram dose was associated with reduced cocaine use in previous trials.
35-1	5979-5983	This	_
35-2	5984-5994	disulfiram	_
35-3	5995-5999	dose	_
35-4	6000-6003	was	_
35-5	6004-6014	associated	_
35-6	6015-6019	with	_
35-7	6020-6027	reduced	_
35-8	6028-6035	cocaine	_
35-9	6036-6039	use	_
35-10	6040-6042	in	_
35-11	6043-6051	previous	_
35-12	6052-6058	trials	_
35-13	6059-6060	.	_

Text=Medication or placebo pill adherence was tracked by observed medication administration at thrice-weekly visits, plus patient self-report for take-home doses.
36-1	6061-6071	Medication	_
36-2	6072-6074	or	_
36-3	6075-6082	placebo	_
36-4	6083-6087	pill	_
36-5	6088-6097	adherence	_
36-6	6098-6101	was	_
36-7	6102-6109	tracked	_
36-8	6110-6112	by	_
36-9	6113-6121	observed	_
36-10	6122-6132	medication	_
36-11	6133-6147	administration	_
36-12	6148-6150	at	_
36-13	6151-6164	thrice-weekly	_
36-14	6165-6171	visits	_
36-15	6172-6173	,	_
36-16	6174-6178	plus	_
36-17	6179-6186	patient	_
36-18	6187-6198	self-report	_
36-19	6199-6202	for	_
36-20	6203-6212	take-home	_
36-21	6213-6218	doses	_
36-22	6219-6220	.	_

Text=This combination of observed and self-reported adherence was used as the primary process indicator (‘ days of medication ’; Table 1) for disulfiram treatment within the group randomized to disulfiram.
37-1	6221-6225	This	_
37-2	6226-6237	combination	_
37-3	6238-6240	of	_
37-4	6241-6249	observed	_
37-5	6250-6253	and	_
37-6	6254-6267	self-reported	_
37-7	6268-6277	adherence	_
37-8	6278-6281	was	_
37-9	6282-6286	used	_
37-10	6287-6289	as	_
37-11	6290-6293	the	_
37-12	6294-6301	primary	_
37-13	6302-6309	process	_
37-14	6310-6319	indicator	_
37-15	6320-6321	(	_
37-16	6322-6323	‘	_
37-17	6324-6328	days	_
37-18	6329-6331	of	_
37-19	6332-6342	medication	_
37-20	6343-6344	’	_
37-21	6345-6346	;	_
37-22	6347-6352	Table	_
37-23	6353-6354	1	_
37-24	6355-6356	)	_
37-25	6357-6360	for	_
37-26	6361-6371	disulfiram	_
37-27	6372-6381	treatment	_
37-28	6382-6388	within	_
37-29	6389-6392	the	_
37-30	6393-6398	group	_
37-31	6399-6409	randomized	_
37-32	6410-6412	to	_
37-33	6413-6423	disulfiram	_
37-34	6424-6425	.	_

Text=A riboflavin tracer in the pills indicated high consistency with self-report.
38-1	6426-6427	A	_
38-2	6428-6438	riboflavin	_
38-3	6439-6445	tracer	_
38-4	6446-6448	in	_
38-5	6449-6452	the	_
38-6	6453-6458	pills	_
38-7	6459-6468	indicated	_
38-8	6469-6473	high	_
38-9	6474-6485	consistency	_
38-10	6486-6490	with	_
38-11	6491-6502	self-report	_
38-12	6503-6504	.	_

Text=All participants were warned of negative consequences of drinking alcohol on disulfiram, strongly discouraged from drinking alcohol during the study, and told that their capsules would be withheld if their breath samples tested positive for alcohol.
39-1	6505-6508	All	_
39-2	6509-6521	participants	_
39-3	6522-6526	were	_
39-4	6527-6533	warned	_
39-5	6534-6536	of	_
39-6	6537-6545	negative	_
39-7	6546-6558	consequences	_
39-8	6559-6561	of	_
39-9	6562-6570	drinking	_
39-10	6571-6578	alcohol	_
39-11	6579-6581	on	_
39-12	6582-6592	disulfiram	_
39-13	6593-6594	,	_
39-14	6595-6603	strongly	_
39-15	6604-6615	discouraged	_
39-16	6616-6620	from	_
39-17	6621-6629	drinking	_
39-18	6630-6637	alcohol	_
39-19	6638-6644	during	_
39-20	6645-6648	the	_
39-21	6649-6654	study	_
39-22	6655-6656	,	_
39-23	6657-6660	and	_
39-24	6661-6665	told	_
39-25	6666-6670	that	_
39-26	6671-6676	their	_
39-27	6677-6685	capsules	_
39-28	6686-6691	would	_
39-29	6692-6694	be	_
39-30	6695-6703	withheld	_
39-31	6704-6706	if	_
39-32	6707-6712	their	_
39-33	6713-6719	breath	_
39-34	6720-6727	samples	_
39-35	6728-6734	tested	_
39-36	6735-6743	positive	_
39-37	6744-6747	for	_
39-38	6748-6755	alcohol	_
39-39	6756-6757	.	_

Text=Substance-use assessments Baseline assessments included the Addiction Severity Index (ASI.
40-1	6758-6771	Substance-use	_
40-2	6772-6783	assessments	_
40-3	6784-6792	Baseline	_
40-4	6793-6804	assessments	_
40-5	6805-6813	included	_
40-6	6814-6817	the	_
40-7	6818-6827	Addiction	_
40-8	6828-6836	Severity	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
40-9	6837-6842	Index	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
40-10	6843-6844	(	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
40-11	6845-6848	ASI	_
40-12	6849-6850	.	_

Text=Thrice weekly during treatment, participants were assessed with urine toxicology and alcohol-breath screens, had study capsules dispensed (disulfiram or placebo) and clinical symptoms monitored.
41-1	6851-6857	Thrice	_
41-2	6858-6864	weekly	_
41-3	6865-6871	during	_
41-4	6872-6881	treatment	_
41-5	6882-6883	,	_
41-6	6884-6896	participants	_
41-7	6897-6901	were	_
41-8	6902-6910	assessed	_
41-9	6911-6915	with	_
41-10	6916-6921	urine	_
41-11	6922-6932	toxicology	_
41-12	6933-6936	and	_
41-13	6937-6951	alcohol-breath	_
41-14	6952-6959	screens	_
41-15	6960-6961	,	_
41-16	6962-6965	had	_
41-17	6966-6971	study	_
41-18	6972-6980	capsules	_
41-19	6981-6990	dispensed	_
41-20	6991-6992	(	_
41-21	6993-7003	disulfiram	_
41-22	7004-7006	or	_
41-23	7007-7014	placebo	_
41-24	7015-7016	)	_
41-25	7017-7020	and	_
41-26	7021-7029	clinical	_
41-27	7030-7038	symptoms	_
41-28	7039-7048	monitored	_
41-29	7049-7050	.	_

Text=Self-reports of day-by-day use of cocaine, alcohol, and other drugs were collected weekly during treatment, using the Timeline Followback method.
42-1	7051-7063	Self-reports	_
42-2	7064-7066	of	_
42-3	7067-7077	day-by-day	_
42-4	7078-7081	use	_
42-5	7082-7084	of	_
42-6	7085-7092	cocaine	_
42-7	7093-7094	,	_
42-8	7095-7102	alcohol	_
42-9	7103-7104	,	_
42-10	7105-7108	and	_
42-11	7109-7114	other	_
42-12	7115-7120	drugs	_
42-13	7121-7125	were	_
42-14	7126-7135	collected	_
42-15	7136-7142	weekly	_
42-16	7143-7149	during	_
42-17	7150-7159	treatment	_
42-18	7160-7161	,	_
42-19	7162-7167	using	_
42-20	7168-7171	the	_
42-21	7172-7180	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
42-22	7181-7191	Followback	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
42-23	7192-7198	method	_
42-24	7199-7200	.	_

Text=When sessions were missed or the participant did not complete treatment, self-report data were collected for the missed data-collection days at subsequent sessions.
43-1	7201-7205	When	_
43-2	7206-7214	sessions	_
43-3	7215-7219	were	_
43-4	7220-7226	missed	_
43-5	7227-7229	or	_
43-6	7230-7233	the	_
43-7	7234-7245	participant	_
43-8	7246-7249	did	_
43-9	7250-7253	not	_
43-10	7254-7262	complete	_
43-11	7263-7272	treatment	_
43-12	7273-7274	,	_
43-13	7275-7286	self-report	_
43-14	7287-7291	data	_
43-15	7292-7296	were	_
43-16	7297-7306	collected	_
43-17	7307-7310	for	_
43-18	7311-7314	the	_
43-19	7315-7321	missed	_
43-20	7322-7337	data-collection	_
43-21	7338-7342	days	_
43-22	7343-7345	at	_
43-23	7346-7356	subsequent	_
43-24	7357-7365	sessions	_
43-25	7366-7367	.	_

Text=Adverse events and blood pressure were tracked weekly during treatment.
44-1	7368-7375	Adverse	_
44-2	7376-7382	events	_
44-3	7383-7386	and	_
44-4	7387-7392	blood	_
44-5	7393-7401	pressure	_
44-6	7402-7406	were	_
44-7	7407-7414	tracked	_
44-8	7415-7421	weekly	_
44-9	7422-7428	during	_
44-10	7429-7438	treatment	_
44-11	7439-7440	.	_

Text=Consistent with our prior work, primary clinical outcome variables were percent of cocaine-negative urines and self-reported days of abstinence during treatment.
45-1	7441-7451	Consistent	_
45-2	7452-7456	with	_
45-3	7457-7460	our	_
45-4	7461-7466	prior	_
45-5	7467-7471	work	_
45-6	7472-7473	,	_
45-7	7474-7481	primary	_
45-8	7482-7490	clinical	_
45-9	7491-7498	outcome	_
45-10	7499-7508	variables	_
45-11	7509-7513	were	_
45-12	7514-7521	percent	_
45-13	7522-7524	of	_
45-14	7525-7541	cocaine-negative	_
45-15	7542-7548	urines	_
45-16	7549-7552	and	_
45-17	7553-7566	self-reported	_
45-18	7567-7571	days	_
45-19	7572-7574	of	_
45-20	7575-7585	abstinence	_
45-21	7586-7592	during	_
45-22	7593-7602	treatment	_
45-23	7603-7604	.	_

Text=Clinical Data Analyses Indicators of cocaine use within-treatment were assessed with ANOVAs including medication (disulfiram, placebo) and CM (CM, no-CM) as between-subject factors (see Table 2).
46-1	7605-7613	Clinical	_
46-2	7614-7618	Data	_
46-3	7619-7627	Analyses	_
46-4	7628-7638	Indicators	_
46-5	7639-7641	of	_
46-6	7642-7649	cocaine	_
46-7	7650-7653	use	_
46-8	7654-7670	within-treatment	_
46-9	7671-7675	were	_
46-10	7676-7684	assessed	_
46-11	7685-7689	with	_
46-12	7690-7696	ANOVAs	_
46-13	7697-7706	including	_
46-14	7707-7717	medication	_
46-15	7718-7719	(	_
46-16	7720-7730	disulfiram	_
46-17	7731-7732	,	_
46-18	7733-7740	placebo	_
46-19	7741-7742	)	_
46-20	7743-7746	and	_
46-21	7747-7749	CM	_
46-22	7750-7751	(	_
46-23	7752-7754	CM	_
46-24	7755-7756	,	_
46-25	7757-7762	no-CM	_
46-26	7763-7764	)	_
46-27	7765-7767	as	_
46-28	7768-7783	between-subject	_
46-29	7784-7791	factors	_
46-30	7792-7793	(	_
46-31	7794-7797	see	_
46-32	7798-7803	Table	_
46-33	7804-7805	2	_
46-34	7806-7807	)	_
46-35	7808-7809	.	_

Text=Clinical outcomes for the parent RCT sample are reported elsewhere.
47-1	7810-7818	Clinical	_
47-2	7819-7827	outcomes	_
47-3	7828-7831	for	_
47-4	7832-7835	the	_
47-5	7836-7842	parent	_
47-6	7843-7846	RCT	_
47-7	7847-7853	sample	_
47-8	7854-7857	are	_
47-9	7858-7866	reported	_
47-10	7867-7876	elsewhere	_
47-11	7877-7878	.	_

Text=Briefly, there were consistent effects favoring CM over no-CM, with mixed findings for disulfiram.
48-1	7879-7886	Briefly	_
48-2	7887-7888	,	_
48-3	7889-7894	there	_
48-4	7895-7899	were	_
48-5	7900-7910	consistent	_
48-6	7911-7918	effects	_
48-7	7919-7927	favoring	_
48-8	7928-7930	CM	_
48-9	7931-7935	over	_
48-10	7936-7941	no-CM	_
48-11	7942-7943	,	_
48-12	7944-7948	with	_
48-13	7949-7954	mixed	_
48-14	7955-7963	findings	_
48-15	7964-7967	for	_
48-16	7968-7978	disulfiram	_
48-17	7979-7980	.	_

Text=fMRI Methods Participants were administered a measure of cognitive-control, the event-related fMRI Color-Word Stroop task, on two occasions: prior to or in the beginning-of-treatment (days between start of study treatment and ‘ beginning-of-treatment ’ scan: M=3 days, SD=5, range= 6 days prior to treatment start −12 days into treatment) and following the end of the 12-week treatment (i.e., post-treatment and prior to 3-month follow-up (days between end of treatment and post-treatment scan: M=20 days, SD=20, range=1–61 days).
49-1	7981-7985	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
49-2	7986-7993	Methods	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
49-3	7994-8006	Participants	_
49-4	8007-8011	were	_
49-5	8012-8024	administered	_
49-6	8025-8026	a	_
49-7	8027-8034	measure	http://maven.renci.org/NeuroBridge/neurobridge#CentralTendencyMeasure
49-8	8035-8037	of	_
49-9	8038-8055	cognitive-control	_
49-10	8056-8057	,	_
49-11	8058-8061	the	_
49-12	8062-8075	event-related	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
49-13	8076-8080	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
49-14	8081-8091	Color-Word	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
49-15	8092-8098	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
49-16	8099-8103	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
49-17	8104-8105	,	_
49-18	8106-8108	on	_
49-19	8109-8112	two	_
49-20	8113-8122	occasions	_
49-21	8123-8124	:	_
49-22	8125-8130	prior	_
49-23	8131-8133	to	_
49-24	8134-8136	or	_
49-25	8137-8139	in	_
49-26	8140-8143	the	_
49-27	8144-8166	beginning-of-treatment	_
49-28	8167-8168	(	_
49-29	8169-8173	days	_
49-30	8174-8181	between	_
49-31	8182-8187	start	_
49-32	8188-8190	of	_
49-33	8191-8196	study	_
49-34	8197-8206	treatment	_
49-35	8207-8210	and	_
49-36	8211-8212	‘	_
49-37	8213-8235	beginning-of-treatment	_
49-38	8236-8237	’	_
49-39	8238-8242	scan	_
49-40	8243-8244	:	_
49-41	8245-8248	M=3	_
49-42	8249-8253	days	_
49-43	8254-8255	,	_
49-44	8256-8260	SD=5	_
49-45	8261-8262	,	_
49-46	8263-8269	range=	_
49-47	8270-8271	6	_
49-48	8272-8276	days	_
49-49	8277-8282	prior	_
49-50	8283-8285	to	_
49-51	8286-8295	treatment	_
49-52	8296-8301	start	_
49-53	8302-8305	−12	_
49-54	8306-8310	days	_
49-55	8311-8315	into	_
49-56	8316-8325	treatment	_
49-57	8326-8327	)	_
49-58	8328-8331	and	_
49-59	8332-8341	following	_
49-60	8342-8345	the	_
49-61	8346-8349	end	_
49-62	8350-8352	of	_
49-63	8353-8356	the	_
49-64	8357-8364	12-week	_
49-65	8365-8374	treatment	_
49-66	8375-8376	(	_
49-67	8377-8381	i.e.	_
49-68	8382-8383	,	_
49-69	8384-8398	post-treatment	_
49-70	8399-8402	and	_
49-71	8403-8408	prior	_
49-72	8409-8411	to	_
49-73	8412-8419	3-month	_
49-74	8420-8429	follow-up	_
49-75	8430-8431	(	_
49-76	8432-8436	days	_
49-77	8437-8444	between	_
49-78	8445-8448	end	_
49-79	8449-8451	of	_
49-80	8452-8461	treatment	_
49-81	8462-8465	and	_
49-82	8466-8480	post-treatment	_
49-83	8481-8485	scan	_
49-84	8486-8487	:	_
49-85	8488-8492	M=20	_
49-86	8493-8497	days	_
49-87	8498-8499	,	_
49-88	8500-8505	SD=20	_
49-89	8506-8507	,	_
49-90	8508-8518	range=1–61	_
49-91	8519-8523	days	_
49-92	8524-8525	)	_
49-93	8526-8527	.	_

Text=On each trial, participants were asked to name the ink color of color-words presented in congruent (e.g., “ RED ” in red ink) or incongruent colors (e.g., “ RED ” in blue ink; see Supplemental Methods for task details).
50-1	8528-8530	On	_
50-2	8531-8535	each	_
50-3	8536-8541	trial	_
50-4	8542-8543	,	_
50-5	8544-8556	participants	_
50-6	8557-8561	were	_
50-7	8562-8567	asked	_
50-8	8568-8570	to	_
50-9	8571-8575	name	_
50-10	8576-8579	the	_
50-11	8580-8583	ink	_
50-12	8584-8589	color	_
50-13	8590-8592	of	_
50-14	8593-8604	color-words	_
50-15	8605-8614	presented	_
50-16	8615-8617	in	_
50-17	8618-8627	congruent	_
50-18	8628-8629	(	_
50-19	8630-8634	e.g.	_
50-20	8635-8636	,	_
50-21	8637-8638	“	_
50-22	8639-8642	RED	_
50-23	8643-8644	”	_
50-24	8645-8647	in	_
50-25	8648-8651	red	_
50-26	8652-8655	ink	_
50-27	8656-8657	)	_
50-28	8658-8660	or	_
50-29	8661-8672	incongruent	_
50-30	8673-8679	colors	_
50-31	8680-8681	(	_
50-32	8682-8686	e.g.	_
50-33	8687-8688	,	_
50-34	8689-8690	“	_
50-35	8691-8694	RED	_
50-36	8695-8696	”	_
50-37	8697-8699	in	_
50-38	8700-8704	blue	_
50-39	8705-8708	ink	_
50-40	8709-8710	;	_
50-41	8711-8714	see	_
50-42	8715-8727	Supplemental	_
50-43	8728-8735	Methods	_
50-44	8736-8739	for	_
50-45	8740-8744	task	_
50-46	8745-8752	details	_
50-47	8753-8754	)	_
50-48	8755-8756	.	_

Text=Stroop mean response times, collected out-of-scanner at time of scanning, were analyzed in SPSS with mixed model ANOVAs including session (beginning-of-treatment, post-treatment) and trial type (incongruent, congruent) as within-subject factors and medication (disulfiram, placebo) and CM (CM, no-CM) conditions as between-subject factors.
51-1	8757-8763	Stroop	_
51-2	8764-8768	mean	_
51-3	8769-8777	response	_
51-4	8778-8783	times	_
51-5	8784-8785	,	_
51-6	8786-8795	collected	_
51-7	8796-8810	out-of-scanner	_
51-8	8811-8813	at	_
51-9	8814-8818	time	_
51-10	8819-8821	of	_
51-11	8822-8830	scanning	_
51-12	8831-8832	,	_
51-13	8833-8837	were	_
51-14	8838-8846	analyzed	_
51-15	8847-8849	in	_
51-16	8850-8854	SPSS	_
51-17	8855-8859	with	_
51-18	8860-8865	mixed	_
51-19	8866-8871	model	_
51-20	8872-8878	ANOVAs	_
51-21	8879-8888	including	_
51-22	8889-8896	session	_
51-23	8897-8898	(	_
51-24	8899-8921	beginning-of-treatment	_
51-25	8922-8923	,	_
51-26	8924-8938	post-treatment	_
51-27	8939-8940	)	_
51-28	8941-8944	and	_
51-29	8945-8950	trial	_
51-30	8951-8955	type	_
51-31	8956-8957	(	_
51-32	8958-8969	incongruent	_
51-33	8970-8971	,	_
51-34	8972-8981	congruent	_
51-35	8982-8983	)	_
51-36	8984-8986	as	_
51-37	8987-9001	within-subject	_
51-38	9002-9009	factors	_
51-39	9010-9013	and	_
51-40	9014-9024	medication	_
51-41	9025-9026	(	_
51-42	9027-9037	disulfiram	_
51-43	9038-9039	,	_
51-44	9040-9047	placebo	_
51-45	9048-9049	)	_
51-46	9050-9053	and	_
51-47	9054-9056	CM	_
51-48	9057-9058	(	_
51-49	9059-9061	CM	_
51-50	9062-9063	,	_
51-51	9064-9069	no-CM	_
51-52	9070-9071	)	_
51-53	9072-9082	conditions	_
51-54	9083-9085	as	_
51-55	9086-9101	between-subject	_
51-56	9102-9109	factors	_
51-57	9110-9111	.	_

Text=Stroop errors on incongruent trials were analyzed with mixed-model ANOVAs including session as a within-subject factor and medication and CM conditions as between-subject factors.
52-1	9112-9118	Stroop	_
52-2	9119-9125	errors	_
52-3	9126-9128	on	_
52-4	9129-9140	incongruent	_
52-5	9141-9147	trials	_
52-6	9148-9152	were	_
52-7	9153-9161	analyzed	_
52-8	9162-9166	with	_
52-9	9167-9178	mixed-model	_
52-10	9179-9185	ANOVAs	_
52-11	9186-9195	including	_
52-12	9196-9203	session	_
52-13	9204-9206	as	_
52-14	9207-9208	a	_
52-15	9209-9223	within-subject	_
52-16	9224-9230	factor	_
52-17	9231-9234	and	_
52-18	9235-9245	medication	_
52-19	9246-9249	and	_
52-20	9250-9252	CM	_
52-21	9253-9263	conditions	_
52-22	9264-9266	as	_
52-23	9267-9282	between-subject	_
52-24	9283-9290	factors	_
52-25	9291-9292	.	_

Text=fMRI data acquisition and pre-processing steps were consistent with our prior work (e.g.,; see Supplemental Methods for details).
53-1	9293-9297	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
53-2	9298-9302	data	_
53-3	9303-9314	acquisition	_
53-4	9315-9318	and	_
53-5	9319-9333	pre-processing	_
53-6	9334-9339	steps	_
53-7	9340-9344	were	_
53-8	9345-9355	consistent	_
53-9	9356-9360	with	_
53-10	9361-9364	our	_
53-11	9365-9370	prior	_
53-12	9371-9375	work	_
53-13	9376-9377	(	_
53-14	9378-9382	e.g.	_
53-15	9383-9384	,	_
53-16	9385-9386	;	_
53-17	9387-9390	see	_
53-18	9391-9403	Supplemental	_
53-19	9404-9411	Methods	_
53-20	9412-9415	for	_
53-21	9416-9423	details	_
53-22	9424-9425	)	_
53-23	9426-9427	.	_

Text=For second-level random-effects analyses, the contrast of interest was the ‘ change in Stroop-effect ’ calculated as [(Incongruentpost> Congruentpost)> (Incongruentpre> Congruentpre)], which assessed changes in Stroop-effect-related activity at post-treatment versus beginning-of-treatment.
54-1	9428-9431	For	_
54-2	9432-9444	second-level	_
54-3	9445-9459	random-effects	_
54-4	9460-9468	analyses	_
54-5	9469-9470	,	_
54-6	9471-9474	the	_
54-7	9475-9483	contrast	_
54-8	9484-9486	of	_
54-9	9487-9495	interest	_
54-10	9496-9499	was	_
54-11	9500-9503	the	_
54-12	9504-9505	‘	_
54-13	9506-9512	change	_
54-14	9513-9515	in	_
54-15	9516-9529	Stroop-effect	_
54-16	9530-9531	’	_
54-17	9532-9542	calculated	_
54-18	9543-9545	as	_
54-19	9546-9547	[	_
54-20	9548-9549	(	_
54-21	9550-9565	Incongruentpost	_
54-22	9566-9567	>	_
54-23	9568-9581	Congruentpost	_
54-24	9582-9583	)	_
54-25	9584-9585	>	_
54-26	9586-9587	(	_
54-27	9588-9602	Incongruentpre	_
54-28	9603-9604	>	_
54-29	9605-9617	Congruentpre	_
54-30	9618-9619	)	_
54-31	9620-9621	]	_
54-32	9622-9623	,	_
54-33	9624-9629	which	_
54-34	9630-9638	assessed	_
54-35	9639-9646	changes	_
54-36	9647-9649	in	_
54-37	9650-9671	Stroop-effect-related	_
54-38	9672-9680	activity	_
54-39	9681-9683	at	_
54-40	9684-9698	post-treatment	_
54-41	9699-9705	versus	_
54-42	9706-9728	beginning-of-treatment	_
54-43	9729-9730	.	_

Text=fMRI results were family-wise-error-corrected at two-tailed pFWE <0.05.
55-1	9731-9735	fMRI	_
55-2	9736-9743	results	_
55-3	9744-9748	were	_
55-4	9749-9776	family-wise-error-corrected	_
55-5	9777-9779	at	_
55-6	9780-9790	two-tailed	_
55-7	9791-9795	pFWE	_
55-8	9796-9797	<	_
55-9	9798-9802	0.05	_
55-10	9803-9804	.	_

Text=To address the primary research question regarding how neural correlates of cognitive-control change across treatment and how these changes relate to engagement with different treatment components, the following approach was taken.
56-1	9805-9807	To	_
56-2	9808-9815	address	_
56-3	9816-9819	the	_
56-4	9820-9827	primary	_
56-5	9828-9836	research	_
56-6	9837-9845	question	_
56-7	9846-9855	regarding	_
56-8	9856-9859	how	_
56-9	9860-9866	neural	_
56-10	9867-9877	correlates	_
56-11	9878-9880	of	_
56-12	9881-9898	cognitive-control	_
56-13	9899-9905	change	_
56-14	9906-9912	across	_
56-15	9913-9922	treatment	_
56-16	9923-9926	and	_
56-17	9927-9930	how	_
56-18	9931-9936	these	_
56-19	9937-9944	changes	_
56-20	9945-9951	relate	_
56-21	9952-9954	to	_
56-22	9955-9965	engagement	_
56-23	9966-9970	with	_
56-24	9971-9980	different	_
56-25	9981-9990	treatment	_
56-26	9991-10001	components	_
56-27	10002-10003	,	_
56-28	10004-10007	the	_
56-29	10008-10017	following	_
56-30	10018-10026	approach	_
56-31	10027-10030	was	_
56-32	10031-10036	taken	_
56-33	10037-10038	.	_

Text=First, changes in fMRI Stroop effect were assessed at the whole brain level (Table 3A).
57-1	10039-10044	First	_
57-2	10045-10046	,	_
57-3	10047-10054	changes	_
57-4	10055-10057	in	_
57-5	10058-10062	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
57-6	10063-10069	Stroop	_
57-7	10070-10076	effect	_
57-8	10077-10081	were	_
57-9	10082-10090	assessed	_
57-10	10091-10093	at	_
57-11	10094-10097	the	_
57-12	10098-10103	whole	_
57-13	10104-10109	brain	_
57-14	10110-10115	level	_
57-15	10116-10117	(	_
57-16	10118-10123	Table	_
57-17	10124-10126	3A	_
57-18	10127-10128	)	_
57-19	10129-10130	.	_

Text=Second, separate whole-brain correlation analyses were carried out between the ‘ change in Stroop effect ’ contrast and the following indicators of treatment engagement: a) CBT sessions (entire sample, N=26); b) CM prizes drawn (subsample randomized to CM, N=14); and c) days of study medication taken (subsample randomized to disulfiram, N=10) (description of variables Table 1; results Table 3B).
58-1	10131-10137	Second	_
58-2	10138-10139	,	_
58-3	10140-10148	separate	_
58-4	10149-10160	whole-brain	_
58-5	10161-10172	correlation	_
58-6	10173-10181	analyses	_
58-7	10182-10186	were	_
58-8	10187-10194	carried	_
58-9	10195-10198	out	_
58-10	10199-10206	between	_
58-11	10207-10210	the	_
58-12	10211-10212	‘	_
58-13	10213-10219	change	_
58-14	10220-10222	in	_
58-15	10223-10229	Stroop	_
58-16	10230-10236	effect	_
58-17	10237-10238	’	_
58-18	10239-10247	contrast	_
58-19	10248-10251	and	_
58-20	10252-10255	the	_
58-21	10256-10265	following	_
58-22	10266-10276	indicators	_
58-23	10277-10279	of	_
58-24	10280-10289	treatment	_
58-25	10290-10300	engagement	_
58-26	10301-10302	:	_
58-27	10303-10304	a	_
58-28	10305-10306	)	_
58-29	10307-10310	CBT	_
58-30	10311-10319	sessions	_
58-31	10320-10321	(	_
58-32	10322-10328	entire	_
58-33	10329-10335	sample	_
58-34	10336-10337	,	_
58-35	10338-10342	N=26	_
58-36	10343-10344	)	_
58-37	10345-10346	;	_
58-38	10347-10348	b	_
58-39	10349-10350	)	_
58-40	10351-10353	CM	_
58-41	10354-10360	prizes	_
58-42	10361-10366	drawn	_
58-43	10367-10368	(	_
58-44	10369-10378	subsample	_
58-45	10379-10389	randomized	_
58-46	10390-10392	to	_
58-47	10393-10395	CM	_
58-48	10396-10397	,	_
58-49	10398-10402	N=14	_
58-50	10403-10404	)	_
58-51	10405-10406	;	_
58-52	10407-10410	and	_
58-53	10411-10412	c	_
58-54	10413-10414	)	_
58-55	10415-10419	days	_
58-56	10420-10422	of	_
58-57	10423-10428	study	_
58-58	10429-10439	medication	_
58-59	10440-10445	taken	_
58-60	10446-10447	(	_
58-61	10448-10457	subsample	_
58-62	10458-10468	randomized	_
58-63	10469-10471	to	_
58-64	10472-10482	disulfiram	_
58-65	10483-10484	,	_
58-66	10485-10489	N=10	_
58-67	10490-10491	)	_
58-68	10492-10493	(	_
58-69	10494-10505	description	_
58-70	10506-10508	of	_
58-71	10509-10518	variables	_
58-72	10519-10524	Table	_
58-73	10525-10526	1	_
58-74	10527-10528	;	_
58-75	10529-10536	results	_
58-76	10537-10542	Table	_
58-77	10543-10545	3B	_
58-78	10546-10547	)	_
58-79	10548-10549	.	_

Text=All analyses were familywise error corrected for multiple comparisons (pFWE = .05) Since level of cocaine abstinence during treatment could affect ‘ change in Stroop-effect ’ across treatment, a separate whole-brain correlation was run between the ‘ change in Stroop effect ’ contrast and cocaine use within-treatment (i.e., percent days self-reported abstinence during treatment; percent cocaine-negative urines during treatment) (Table 3B).
59-1	10550-10553	All	_
59-2	10554-10562	analyses	_
59-3	10563-10567	were	_
59-4	10568-10578	familywise	_
59-5	10579-10584	error	_
59-6	10585-10594	corrected	_
59-7	10595-10598	for	_
59-8	10599-10607	multiple	_
59-9	10608-10619	comparisons	_
59-10	10620-10621	(	_
59-11	10622-10626	pFWE	_
59-12	10627-10628	=	_
59-13	10629-10632	.05	_
59-14	10633-10634	)	_
59-15	10635-10640	Since	_
59-16	10641-10646	level	_
59-17	10647-10649	of	_
59-18	10650-10657	cocaine	_
59-19	10658-10668	abstinence	_
59-20	10669-10675	during	_
59-21	10676-10685	treatment	_
59-22	10686-10691	could	_
59-23	10692-10698	affect	_
59-24	10699-10700	‘	_
59-25	10701-10707	change	_
59-26	10708-10710	in	_
59-27	10711-10724	Stroop-effect	_
59-28	10725-10726	’	_
59-29	10727-10733	across	_
59-30	10734-10743	treatment	_
59-31	10744-10745	,	_
59-32	10746-10747	a	_
59-33	10748-10756	separate	_
59-34	10757-10768	whole-brain	_
59-35	10769-10780	correlation	_
59-36	10781-10784	was	_
59-37	10785-10788	run	_
59-38	10789-10796	between	_
59-39	10797-10800	the	_
59-40	10801-10802	‘	_
59-41	10803-10809	change	_
59-42	10810-10812	in	_
59-43	10813-10819	Stroop	_
59-44	10820-10826	effect	_
59-45	10827-10828	’	_
59-46	10829-10837	contrast	_
59-47	10838-10841	and	_
59-48	10842-10849	cocaine	_
59-49	10850-10853	use	_
59-50	10854-10870	within-treatment	_
59-51	10871-10872	(	_
59-52	10873-10877	i.e.	_
59-53	10878-10879	,	_
59-54	10880-10887	percent	_
59-55	10888-10892	days	_
59-56	10893-10906	self-reported	_
59-57	10907-10917	abstinence	_
59-58	10918-10924	during	_
59-59	10925-10934	treatment	_
59-60	10935-10936	;	_
59-61	10937-10944	percent	_
59-62	10945-10961	cocaine-negative	_
59-63	10962-10968	urines	_
59-64	10969-10975	during	_
59-65	10976-10985	treatment	_
59-66	10986-10987	)	_
59-67	10988-10989	(	_
59-68	10990-10995	Table	_
59-69	10996-10998	3B	_
59-70	10999-11000	)	_
59-71	11001-11002	.	_

Text=To check whether the regions associated with engagement in different aspects of treatment overlapped or were simply reflections of the same regions associated with cocaine abstinence during treatment, the separate correlation analyses were entered into formal conjunction analyses (see Supplemental Material for detailed methods).
60-1	11003-11005	To	_
60-2	11006-11011	check	_
60-3	11012-11019	whether	_
60-4	11020-11023	the	_
60-5	11024-11031	regions	_
60-6	11032-11042	associated	_
60-7	11043-11047	with	_
60-8	11048-11058	engagement	_
60-9	11059-11061	in	_
60-10	11062-11071	different	_
60-11	11072-11079	aspects	_
60-12	11080-11082	of	_
60-13	11083-11092	treatment	_
60-14	11093-11103	overlapped	_
60-15	11104-11106	or	_
60-16	11107-11111	were	_
60-17	11112-11118	simply	_
60-18	11119-11130	reflections	_
60-19	11131-11133	of	_
60-20	11134-11137	the	_
60-21	11138-11142	same	_
60-22	11143-11150	regions	_
60-23	11151-11161	associated	_
60-24	11162-11166	with	_
60-25	11167-11174	cocaine	_
60-26	11175-11185	abstinence	_
60-27	11186-11192	during	_
60-28	11193-11202	treatment	_
60-29	11203-11204	,	_
60-30	11205-11208	the	_
60-31	11209-11217	separate	_
60-32	11218-11229	correlation	_
60-33	11230-11238	analyses	_
60-34	11239-11243	were	_
60-35	11244-11251	entered	_
60-36	11252-11256	into	_
60-37	11257-11263	formal	_
60-38	11264-11275	conjunction	_
60-39	11276-11284	analyses	_
60-40	11285-11286	(	_
60-41	11287-11290	see	_
60-42	11291-11303	Supplemental	_
60-43	11304-11312	Material	_
60-44	11313-11316	for	_
60-45	11317-11325	detailed	_
60-46	11326-11333	methods	_
60-47	11334-11335	)	_
60-48	11336-11337	.	_

Text=For all fMRI correlation analyses, if variables were not normally distributed, rank-order correlations were used as a non-parametric alternative.
61-1	11338-11341	For	_
61-2	11342-11345	all	_
61-3	11346-11350	fMRI	_
61-4	11351-11362	correlation	_
61-5	11363-11371	analyses	_
61-6	11372-11373	,	_
61-7	11374-11376	if	_
61-8	11377-11386	variables	_
61-9	11387-11391	were	_
61-10	11392-11395	not	_
61-11	11396-11404	normally	_
61-12	11405-11416	distributed	_
61-13	11417-11418	,	_
61-14	11419-11429	rank-order	_
61-15	11430-11442	correlations	_
61-16	11443-11447	were	_
61-17	11448-11452	used	_
61-18	11453-11455	as	_
61-19	11456-11457	a	_
61-20	11458-11472	non-parametric	_
61-21	11473-11484	alternative	_
61-22	11485-11486	.	_

Text=Additional analyses addressed whether ‘ change in Stroop-effect ’ differed by randomly assigned treatment condition in separate analyses: a) CM versus no-CM groups, b) disulfiram versus placebo groups.
62-1	11487-11497	Additional	_
62-2	11498-11506	analyses	_
62-3	11507-11516	addressed	_
62-4	11517-11524	whether	_
62-5	11525-11526	‘	_
62-6	11527-11533	change	_
62-7	11534-11536	in	_
62-8	11537-11550	Stroop-effect	_
62-9	11551-11552	’	_
62-10	11553-11561	differed	_
62-11	11562-11564	by	_
62-12	11565-11573	randomly	_
62-13	11574-11582	assigned	_
62-14	11583-11592	treatment	_
62-15	11593-11602	condition	_
62-16	11603-11605	in	_
62-17	11606-11614	separate	_
62-18	11615-11623	analyses	_
62-19	11624-11625	:	_
62-20	11626-11627	a	_
62-21	11628-11629	)	_
62-22	11630-11632	CM	_
62-23	11633-11639	versus	_
62-24	11640-11645	no-CM	_
62-25	11646-11652	groups	_
62-26	11653-11654	,	_
62-27	11655-11656	b	_
62-28	11657-11658	)	_
62-29	11659-11669	disulfiram	_
62-30	11670-11676	versus	_
62-31	11677-11684	placebo	_
62-32	11685-11691	groups	_
62-33	11692-11693	.	_

Text=Since treatment group differences in ‘ change in Stroop-effect ’ could be influenced by beginning-of-treatment group differences, potentially confounding beginning-of-treatment differences between treatment groups were assessed by comparing beginning-of-treatment Stroop-effect (Incongruentpre> Congruentpre trials) by CM (CM> no-CM) and medication (disulfiram> placebo) randomization status.
63-1	11694-11699	Since	_
63-2	11700-11709	treatment	_
63-3	11710-11715	group	_
63-4	11716-11727	differences	_
63-5	11728-11730	in	_
63-6	11731-11732	‘	_
63-7	11733-11739	change	_
63-8	11740-11742	in	_
63-9	11743-11756	Stroop-effect	_
63-10	11757-11758	’	_
63-11	11759-11764	could	_
63-12	11765-11767	be	_
63-13	11768-11778	influenced	_
63-14	11779-11781	by	_
63-15	11782-11804	beginning-of-treatment	_
63-16	11805-11810	group	_
63-17	11811-11822	differences	_
63-18	11823-11824	,	_
63-19	11825-11836	potentially	_
63-20	11837-11848	confounding	_
63-21	11849-11871	beginning-of-treatment	_
63-22	11872-11883	differences	_
63-23	11884-11891	between	_
63-24	11892-11901	treatment	_
63-25	11902-11908	groups	_
63-26	11909-11913	were	_
63-27	11914-11922	assessed	_
63-28	11923-11925	by	_
63-29	11926-11935	comparing	_
63-30	11936-11958	beginning-of-treatment	_
63-31	11959-11972	Stroop-effect	_
63-32	11973-11974	(	_
63-33	11975-11989	Incongruentpre	_
63-34	11990-11991	>	_
63-35	11992-12004	Congruentpre	_
63-36	12005-12011	trials	_
63-37	12012-12013	)	_
63-38	12014-12016	by	_
63-39	12017-12019	CM	_
63-40	12020-12021	(	_
63-41	12022-12024	CM	_
63-42	12025-12026	>	_
63-43	12027-12032	no-CM	_
63-44	12033-12034	)	_
63-45	12035-12038	and	_
63-46	12039-12049	medication	_
63-47	12050-12051	(	_
63-48	12052-12062	disulfiram	_
63-49	12063-12064	>	_
63-50	12065-12072	placebo	_
63-51	12073-12074	)	_
63-52	12075-12088	randomization	_
63-53	12089-12095	status	_
63-54	12096-12097	.	_

